Biosimilars are prompting a healthcare revolution globally, enabling greater patient access to life-changing biologic therapies while enhancing healthcare sustainability worldwide.
A look inside any healthcare system would undoubtedly reveal the struggle to reduce costs yet offer the best treatments possible for patients. Health authorities and payers search for ways to balance bringing innovative drugs to areas of unmet need, while maintaining choice and access for patients and providers in more established diseases. This is especially important for chronic immunology-related conditions, where biologic therapies (large, complex biological compounds that are made by living cells rather than being manufactured chemically like most other drugs) can have a transformative impact for patients. It is within this interplay that biosimilars can play an important role in helping patients, physicians, payers and society as a whole.
A closer look at biologics and biosimilars
Biosimilars are medicines that are highly similar (but not identical) to currently available biologic therapies known as originators.1 Based on available products (whose patents have expired) the biosimilars aim to reduce treatment costs while also being nearly identical to their reference biologics.2,3 Biosimilars can cost-effectively enable expanded access to life-changing treatments while also incorporating innovation to bring a best-in-class experience for patients and physicians.